TGM6

Across TCGA pan-cancer cohorts, TGM6 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated TGM6 data layer compared with 13 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher TGM6 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated TGM6 expression acts as an unfavorable survival marker, although some lineages such as STAD and UCEC show a favorable association.

STAD, UCEC, and LIHC are the cancer types where TGM6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Median	II,III,IV	1.000	0.375	.022	18	view →
UCEC	DFS	Median	III,IV	1.000	0.536	.028	18	view →
LIHC	OS	Median	All	0.156	0.774	.007	12	view →
PRAD	DFS	Median	All	0.412	0.776	<.001	6	view →
LUSC	OS	Median	III,IV	0.112	0.664	.003	6	view →
SKCM	OS	Median	III,IV	0.985	0.768	.008	5	view →
LUAD	OS	Median	All	0.955	0.805	.034	4	view →
HNSC	DFS	Median	II,III,IV	1.000	0.678	.036	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

TGM6–STAD (DFS)

Open the STAD breakdown →